Randomized Trial of Preemptive Treatment With Oral Valganciclovir Compared With IV Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

Trial Profile

Randomized Trial of Preemptive Treatment With Oral Valganciclovir Compared With IV Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2013

At a glance

  • Drugs Valganciclovir (Primary) ; Ganciclovir
  • Indications Cytomegalic inclusion disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jul 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 18 Jan 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 22 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top